These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Thrombin inhibitors in women on oral contraceptives.
    Author: Guagnellini E, Bertolini G, Cappelletti M, Colombo G.
    Journal: Acta Haematol; 1981; 65(3):205-10. PubMed ID: 6165217.
    Abstract:
    Progressive antithrombin activity and the immunological levels of antithrombin III, alpha 2-macroglobulin, and alpha 1-antitrypsin were measured in women at various intervals during treatment with oral contraceptives and in a group of untreated women. No significant changes were observed in any of the above parameters. In both control and treated women, there was a positive statistical correlation between progressive antithrombin activity and antithrombin III immunological levels, whereas no correlation was found between the former and alpha 1-antitrypsin or alpha 2-macroglobulin immunological levels. This study questions the possibility of thrombin inhibitors being selective signs of hypercoagulability during treatment with oral contraceptives. Clinical research was conducted into the progressive antithrombin activity of plasma and the concentrations of AT-3(antithrombin-3), alpha2-M(alpha2-macroglobulin), and alphal-AT(alphal-antitrypsin) of women taking OCs (oral contraceptives). Women at various intervals during low-dose OC therapy were tested and compared with women not taking OCs. No significant changes were observed in any of these 3 parameters. In both groups of women the progressive antithrombin activity of plasma decreased gradually during the menstrual cycle, with the low at day 21. In both groups, there was a positive correlation between progressive antithrombin activity and antithrombin-3 immunological levels, but no correlation was found between the former and either of the other 2 factors. Findings from this study do not support previous reports that OC treatment lowers AT-3 levels. AT-3 cannot be considered a selective sign of hyper-coagulability during OC treatment.
    [Abstract] [Full Text] [Related] [New Search]